Endovascular Repair of Aortic Disease: A Venture Capital Perspective

ABSTRACT

Endovascular devices for the treatment of abdominal and thoracic aortic disease are poised to become the next $1 billion medical device market. A shift from open repair to endovascular repair, advances in technology, screening initiatives, and new indications are driving this growth. Although billion-dollar medical device markets are rare, this field is fraught with risk and uncertainty for startups and their venture capital investors. Technological hurdles, daunting clinical and regulatory timelines, market adoption issues, and entrenched competitors pose significant barriers to successful new venture creation. In fact, the number of aortic endografts that have failed to reach commercialization or have been pulled from the market exceeds the number of Food and Drug Administration–approved endografts in the United States. This article will shed some light on the venture capital mind-set and decision-making paradigm in the context of aortic disease.

KEYWORDS

Venture capital - endovascular therapy - endografts - aortic disease - aneurysms

REFERENCES

• 1 Platzer M. Patient Capital. National Venture Capital Association. Available at: http://nvca.org/pdf/NVCAPatientCapital.pdf Accessed December 30, 2008
• 2 Ackerly D C, Valverde A M, Diener L W et al.. Fueling innovation in medical devices (and beyond): venture capital in health care.  Health Aff (Millwood). 2009;  28 w68-w75
• 3 National Venture Capital Association .Available at: http://www.nvca.org/pdf/q208VCPerformanceRelease.pdf Accessed December 31, 2008
• 4 Yearbook 2008 National Venture Capital Association. Available at: http://nvca.org/pdf/NVCAYearbook2008.pdf Accessed December 18, 2008
• 5 Ferrari R. Value Creation for Health Care Startups. In: Health Care Venture Capital Best Practices. Boston, MA; Aspatore 2008
• 6 VenturXpert database. Available at: http://vx.thomsonib.com/NASApp/VxComponent/VXMain.jsp Accessed December 29, 2008
• 7 U.S. Venture Partners .Investment approach page. Available at: http://www.usvp.com/html_vers/approach.html Accessed January 5, 2009
• 8 Saftlas H. Industry Surveys—Healthcare: Pharmaceuticals. New York, NY; Standard & Poors 2008
• 9 Stewart K, Hu C, Cal L. Medtech Analyzer: October 2008: Buckle Up, Things May Get Bumpy. Credit Suisse 2008
• 10 Medtronic 2008 10K SEC filing. Available at: http://investorrelations.medtronic.com/secfiling.cfm?filingID=897101-08-1392 Accessed January 5, 2009
• 11 Lee T, Yee C. Medtronic, Inc: Premier Franchise in Medical Technology. San Francisco, CA; Piper Jaffray 2008
• 12 U.S. Market for Peripheral Vascular Devices .Vancouver, Canada; iData Research Inc. 2007
• 13 U.S. Markets for Peripheral Vascular Devices .Toronto, Canada; Millenium Research Group 2007
• 14 Leurs L J, Buth J, Laheij R J. Long-term results of endovascular abdominal aortic aneurysm treatment with the first generation of commercially available stent grafts.  Arch Surg. 2007;  142 33-41
• 15 van Marrewijk C J, Leurs L J, Vallabhaneni S R et al.. Risk-adjusted outcome analysis of endovascular abdominal aortic aneurysm repair in a large population: how do stent-grafts compare?.  J Endovasc Ther. 2005;  12 417-429
• 16 EVAR Trial Participants . Endovascular aneurysm repair versus open repair in patients with abdominal aortic aneurysm (EVAR trial 1): randomised controlled trial.  Lancet. 2005;  365 2179-2186
• 17 Prinssen M, Verhoeven E L, Buth J et al.. A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms.  N Engl J Med. 2004;  351 1607-1618
• 18 Moise M A, Woo E Y, Velazquez O C et al.. Barriers to endovascular aortic aneurysm repair: past experience and implications for future device development.  Vasc Endovascular Surg. 2006;  40 197-203
• 19 Makaroun M S, Dillavou E D, Kee S T et al.. Endovascular treatment of thoracic aortic aneurysms: results of the phase II multicenter trial of the GORE TAG thoracic endoprosthesis.  J Vasc Surg. 2005;  41 1-9
• 20 Ricotta J J, Oderich G S. Fenestrated and branched stent grafts.  Perspect Vasc Surg Endovasc Ther. 2008;  20 174-187 discussion 188-189
• 21 Donas K P, Kafetzakis A, Umscheid T et al.. Vascular endostapling: new concept for endovascular fixation of aortic stent-grafts.  J Endovasc Ther. 2008;  15 499-503
• 22 Rosen R J, Green R M. Endoleak management following endovascular aneurysm repair.  J Vasc Interv Radiol. 2008;  19(suppl) S37-S43
• 23 Prinssen M, Verhoeven E L, Buth J et al.. A randomized trial comparing conventional and endovascular repair of abdominal aortic aneurysms.  N Engl J Med. 2004;  351 1607-1618
• 24 Burns L R, Housman M G, Robinson C A. Market entry and exit by biotech and device companies funded by venture capital.  Health Aff (Millwood). 2009;  28 w76-w86
• 25 Motley Rice .Guidant Ancure Endograft System page. Available at: http://motleyrice.com/medical/devices/GuidantAncureEndograftSystem/default.asp Accessed December 30, 2008
• 26 Wallack T. Boston Scientific cited by FDA for procedures. The Boston Globe; 2007. Available at: http://www.boston.com/business/healthcare/articles/2007/09/08/boston_scientific_cited_by_fda_for_procedures/ Accessed December 29, 2008
• 27 Boston Scientific 2006 10K SEC filing. Available at: http://www.secinfo.com/d1znFa.uhw.htm Accessed January 5, 2009
• 28 Katzen B T, MacLean A A. Past, present, and future endograft devices.  Tech Vasc Interv Radiol. 2005;  8 16-21
• 29 Edwards Lifesciences .Newsroom page. Available at: http://www.edwards.com/newsroom/nr20040406.htm Accessed December 30, 2008
• 30 Parodi F E, Mao D, Ennis T L et al.. Suppression of experimental abdominal aortic aneurysms in mice by treatment with pyrrolidine dithiocarbamate, an antioxidant inhibitor of nuclear factor-kappaB.  J Vasc Surg. 2005;  41 479-489